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Objectives: In our previous studies we reported a panel of 24 miRNAs that allowed discrimination between blood
of lung tumor patients independent of the histological subtype and blood of healthy controls with an accuracy
of 95.4% [94.9%-95.9%]. Here, we now separately analyzed the miRNA expression in blood of non-small cell lung
cancer (NSCLC), including squamous cell lung cancer and adenocarcinoma, and small cell lung cancer (SCLC) patients.
Patients and methods: In total, we examined the expression levels of 1,205 miRNAs in blood samples from 20
patients from each of the three histological groups and determined differentially expressed miRNAs between
histological subtypes and metastatic and non-metastatic lung cancer. We further determined the overlap of miRNAs
expressed in each subgroup with the 24-miRNA signature of lung tumor patients.
Results: Based on a raw p-value < 0.05, only 18 blood-borne miRNAs were differentially expressed between patients
with adenocarcinoma and with squamous cell lung carcinoma, 11 miRNAs between adenocarcinoma and SCLC, and
2 between squamous cell lung carcinoma and SCLC. Likewise, the comparison based on a fold change of 1.5 did not
reveal major differences of the blood-borne miRNA expression pattern between NSCLC and SCLC. In addition, we
found a large overlap between the blood-borne miRNAs detected in the three histological subgroups and the
previously described 24-miRNA signature that separates lung cancer patients form controls. We identified several
miRNAs that allowed differentiating between metastatic and non-metastatic tumors both in blood of patients with
adenocarcinoma and in blood of patients with SCLC.
Conclusion: There is a common miRNA expression pattern in blood of lung cancer patients that does not allow a
reliable further subtyping into NSCLC or SCLC, or into adenocarcinoma and squamous cell lung cancer. The previously
described 24-miRNA signature for lung cancer appears not primarily dependent on histological subtypes. However,
metastatic adenocarcinoma and SCLC can be predicted with 75% accuracy.
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Lung cancer is worldwide the leading cause of cancer re-
lated deaths in both men and women with estimated
1,608,055 (12.72%) new cases and 1,376,579 (18.2%) can-
cer deaths in 2008 ([1] available from: http://globocan.
iarc.fr, accessed on 09/01/2013). Primarily, lung cancer is
divided into two main histological subtypes depending
on their cells of origin. Non-small cell lung cancer
(NSCLC) account for about 80% of all lung cancers and
are further divided by their origin into adenocarcinoma
(Adeno-Ca, about 40%), squamous cell carcinoma (sqCLC,
about 30%) and large cell carcinoma (about 9%). Small cell
lung cancer (SCLC) is far more aggressive than NSCLC
and accounts for about 15% of all lung cancers. The classi-
fication into the different histological lung cancer types
plays a prominent role in clinical management and prog-
nosis of the disease [2].
As most SCLC have spread to other parts of the body
at the time of diagnosis surgery is often ineffective, but
they respond well to chemotherapy and radiation. For
early stage I and II NSCLCs, surgery is the treatment of
choice. However, as these two stages combined account
for only 25 to 30% of all patients with lung cancer the
most common treatment is systemic therapy (chemo- or
targeted therapy) and/or radiotherapy [3-5]. Among
NSCLCs, adenocarcinoma and squamous cell carcinoma
differ with regards to the clinical management and the
prognosis. Adenocarcinoma are, for example, more likely
to metastasize to the lymph nodes and the brain than
squamous cell lung cancer [6]. Lung cancer diagnosis
and subclassification is normally based on light micro-
scopic criteria but an accurate diagnosis of histological
lung cancer subtypes is often hampered by small tissue
biopsies and high observer variability [7-9].
Since several years, microRNAs (miRNAs) have shifted
more and more into focus as cancer biomarkers. MiR-
NAs are small non-coding RNA molecules that are in-
volved in many physiological and pathological processes
due to their ability to regulate the expression of most
human genes. In the recent past, it was shown that miR-
NAs are tissue specific and suitable to classify human
cancers [10,11]. Especially for lung cancer it was recently
shown that classification of different subtypes due to the
miRNA expression pattern is possible [12-15]. While
these studies were done on lung cancer tissue or cells,
there is an increasing number of investigations on miR-
NAs in the circulation as potential biomarkers [16-27].
In our previous studies, we were able to show that
blood-based miRNA expression profiles differentiate be-
tween lung cancer patients, patients with COPD and
healthy individuals [24,26]. While these studies show
that various diseases including lung cancer can clearly
be differentiated from controls by a blood-borne miRNA
pattern, there is significant less evidence that histologicalsubtypes of a disease can also be classified by blood-borne
miRNA expression pattern. Here we set out to analyze the
miRNA expression of different histological lung cancer
subtypes. In detail, we investigated the miRNA expression
profile of blood from patients with non-small cell lung
cancer, including squamous cell lung cancer and adeno-
carcinoma, and small cell lung cancer.
Results
Overall miRNA expression in blood of lung cancer patients
Previously, we reported a panel of 24 blood-borne miR-
NAs that allowed discrimination between lung tumor
patients and healthy controls [24]. Here, we analyzed the
expression of blood-borne miRNAs in patients with
NSCLC (squamous cell lung cancer, adenocarcinoma) or
SCLC. In detail, we examined the expression levels of
1,205 miRNAs in whole blood samples collected in PAX-
gene blood RNA tubes. RNA expression profiles were
generated from 20 patients with SCLC and 40 patients
with NSCLC including 20 adenocarcinoma and 20 squa-
mous cell lung carcinoma. Of the 1,205 analyzed miRNAs,
872 miRNAs were not detected in any adenocarcinoma
sample, 868 miRNAs not in squamous cell lung cancer
samples and 853 miRNAs not in SCLC samples. Besides
these non-detected miRNAs, we found large numbers of
miRNAs that were detected in all samples of each group.
Specifically, we found 155 miRNAs that were detected in
all 20 adenocarcinoma samples, 158 miRNAs in all squa-
mous cell lung cancer samples, and 148 miRNAs in all
SCLC samples. Notably, we found a high overlap of 134
miRNAs that were expressed in all 60 samples. The de-
tected miRNAs per group and the overlaps between the
groups are shown in Figure 1A. Figure 1 B shows the heat-
map of the unsupervised hierarchical clustering based on
the 134 miRNAs detected in all samples.
Differential miRNA expression profiles in blood of
patients with histological different lung cancer types
To further analyze the similarity/difference between the
miRNA pattern of the subtypes, we performed two-
tailed unpaired t-tests for each of the 1,205 miRNA and
all samples of each of the three subgroups. After adjust-
ing the p-values by the Benjamini-Hochberg approach,
we did not find any significantly deregulated miRNAs
(p < 0.05). Without adjustment, we found only 18 miR-
NAs differentially expressed between blood samples of
patients with adenocarcinoma and patients with squa-
mous cell lung carcinoma, 11 differently expressed miR-
NAs for the comparison between adenocarcinoma and
SCLC, and 2 miRNAs for the comparison between squa-
mous cell lung carcinoma and SCLC, each with a raw
p-value < 0.05. Hsa-let-7c was the only deregulated miRNA
in the comparison between NSCLC and SCLC. The re-
spective miRNAs and raw p-values are summarized in
Figure 1 Overall miRNA expression in blood of lung cancer
patients. A: Venn-diagram of detected miRNAs per group. Each
circle of the three-way Venn-diagram indicates the numbers of
miRNAs that are detected in whole blood samples of either all 20
adenocarcinoma patients, all 20 squamous cell lung cancer patients,
or all 20 SCLC patients. Adeno-Ca = adenocarcinoma, sqCLC = squamous
cell lung cancer, SCLC = small cell lung cancer. B: Heatmap of the
134 miRNAs detected in all analyzed 60 patient samples. Each
column represents a blood sample and each row represents a miRNA.
The miRNA expression values are visualized by the red-green color
code, where green means low expression and red means high
expression. The colored bars under the dendrogram indicate the
histological subtype, the smoking status, the gender, and the metastatic
state of the respective samples (red = squamous cell lung cancer
(sqCLC), blue = adenocarcinoma, yellow = SCLC, pink = metastasis
(M1a or M1b), cyan = no metastasis (M0), black = no information on
metastasis state, skyblue = male, darkred = female, grey = current or
former smoker, white = never-smoker).
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found for comparisons with adenocarcinoma. These results
indicate that there are no major differences of the blood-
borne miRNA expression pattern between NSCLC and
SCLC.
The above mentioned findings were largely confirmed
when we focused on miRNAs with a fold change of at
least 1.5 independent of the p-value. The comparison of
adenocarcinoma samples with squamous cell lung cancer
samples yielded the highest number of deregulated miR-
NAs (n = 20) including five miRNAs with a raw p-value
<0.05. The comparison between adenocarcinoma and
SCLC revealed 17 miRNAs including two miRNAs with
p-values <0.05, and the comparison between squamous
cell lung carcinoma and SCLC revealed 7 miRNAs includ-
ing one with a p-value <0.05. The same number of deregu-
lated miRNAs was found for NSCLC vs. SCLC, but none
of those 7 miRNAs had a p-value <0.05 (Table 2).
Overall, the above data indicate a high degree of simi-
larity between the blood-borne miRNA signatures of the
different subtypes of lung cancer. This is also visualized
in Figure 2 that shows a heatmap with the 50 miRNAs
with highest variance and all samples. There is no clear
clustering into the three different histological subtypes.
However, we found few miRNAs that were deregulated
in the same direction in two or three of the comparisons.
The miRNAs hsa-miR-296-5p, hsa-miR-378*, hsa-miR-
185, and hsa-miR-550a* were down regulated in adenocar-
cinoma compared to squamous cell lung carcinoma and
in adenocarcinoma compared to SCLC. In the same two
comparisons hsa-miR-107 was over-expressed in adeno-
carcinoma. MiRNA hsa-let-7c was up regulated in adeno-
carcinoma compared to SCLC and in NSCLC compared
to SCLC.
For validation purposes we performed quantitative
Real Time PCR (RT-qPCR) on five miRNAs using an
Table 1 Deregulated miRNAs based on raw p-values < 0.05
MiRNA Adenocarcinoma vs squamous
cell lung cancer
Adenocarcinoma vs SCLC Squamous cell lung
cancer vs SCLC
NSCLC vs SCLC
hsa-miR-296-5p 0.009293704 0.002492158 - -
hsa-miR-4286 - - 0.042230044 -
hsa-miR-125b - 0.028149193 - -
hsa-miR-222 - - 0.04703922 -
hsa-miR-1202 0.007974179 - - -
hsa-miR-30c - 0.041578614 - -
hsa-miR-30d 0.023430857 - - -
hsa-miR-484 - 0.030142088 - -
hsa-miR-191 0.037639111 - - -
hsa-miR-378* 0.019775161 0.010497338 - -
hsa-miR-494 0.019335653 - - -
hsa-miR-20a 0.013479972 - - -
hsa-miR-93* 0.047492422 - - -
hsa-miR-185 0.021057518 0.02356637 - -
hsa-miR-93 0.025342321 - - -
hsa-miR-550a* 0.031935527 0.021650736 - -
hsa-miR-423-3p - 0.014698713 - -
hsa-let-7c - 0.036109015 - 0.038753591
hsa-let-7f 0.043924552 - - -
hsa-let-7 g 0.015803657 - - -
hsa-miR-17 0.017017848 - - -
hsa-miR-16 0.04337876 - - -
hsa-miR-664 0.029957884 - - -
hsa-miR-26b 0.044474487 - - -
hsa-miR-146a - 0.033986273 - -
hsa-miR-107 0.031934222 0.023377571 - -
miRNAs with raw p-value <0.05. bold font = down-regulated in first group of comparison, normal font = up-regulated in first group of comparison.
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by the microarray approach. As shown in Additional file 1:
Figure S1, we confirmed most of the measured miRNAs.
Next, we analyzed the overlap between the blood-
borne miRNAs that were expressed in the different
histological subtypes and a set of 24 deregulated miR-
NAs that was previously shown by our group to separ-
ate lung tumor patients and controls with high accuracy
[24]. Out of those 24 blood-borne miRNAs, 17 miRNAs
were detected in the blood samples of all 20 adenocar-
cinoma patients, 20 miRNAs in all squamous cell
lung carcinoma patients, and likewise 20 miRNAs in all
SCLC patients (see Additional file 2: Table S1). The ex-
tended overlap of the 24-miRNA signature with each of
the three histological subgroups indicates that the signa-
ture does not primarily depend on a histological sub-
type. The same analysis was performed with deregulated
miRNAs identified in other studies on lung cancereither on whole blood samples or on tissue specimen.
We have to point out that the studies on whole blood
were mostly based on the identification of deregulated
miRNAs between blood from lung cancer patients and
blood from healthy controls or patients with other lung
diseases and not on the differentiation of the different
histological lung cancer subtypes [22,26,28,29]. Studies
that compared miRNAs between histological subgroups
of lung cancer did not use whole blood as source of
the miRNA but are based on the analysis of FFPE, biop-
sies, brushing specimens, fine needle aspirations etc.
[12-15,30-32]. Additional file 2: Table S1 gives an over-
view of this analysis. The majority of miRNAs identified
in the above mentioned studies on whole blood samples
from lung cancer patients and controls and on tissue
samples from different histological lung cancer sub-
groups were detected in most of the blood samples ana-
lyzed in the present study.
Table 2 Deregulated miRNAs based on fold changes >1.5







hsa-miR-320b 1.565908352 - 1.647174369 -
hsa-miR-320a 1.682325336 - - -
hsa-miR-16-2* - 1.556819993 1.584825817 1.547144675
hsa-miR-425* - 1.558378991 - -
hsa-miR-1825 - 1.601678188 - -
hsa-miR-126 1.891966989 - - -
hsa-miR-19a 1.649266976 2.162558226 - 1.578154988
hsa-miR-144* 2.055635088 - - -
hsa-miR-1238 - 1.615812614 - -
hsa-miR-1202 1.794851186 - - -
hsa-miR-33b* - 3.71072872 2.277178734 3.455716247
hsa-miR-3180-3p - 1.540492953 - -
hsa-miR-21 1.576532119 1.517125311 - -
hsa-miR-494 3.238384244 2.523949933 - 1.604162158
hsa-miR-125b - 1.893914674 - 1.576963025
hsa-miR-4286 - - 1.606159073 1.505950661
hsa-miR-3651 1.507544659 - - -
hsa-miR-940 1.513643787 - - -
hsa-miR-20a 1.807832821 1.644649446 - -
hsa-miR-1228 1.613581053 - - -
hsa-miR-3162 1.560608345 - - -
hsa-miR-98 1.657974523 - - -
hsa-miR-96 1.65850084 1.519616853 - -
hsa-miR-191* - 1.557935486 - -
hsa-let-7b - - 1.633347369 -
hsa-let-7a 1.545768531 - 1.522487952 -
hsa-let-7 g 1.580842517 - - -
hsa-miR-142-3p 2.29109294 2.221864576 - 1.563956799
hsa-miR-197 - 1.506054329 - -
hsa-miR-26b 2.299936662 - 1.58391195 -
hsa-miR-146a - 1.681236456 - -
hsa-miR-1281 - 1.501429345 - -
hsa-miR-1280 1.601529185 - - -
miRNAs with fold changes >1.5. bold font = down-regulated in first group of comparison, normal font = up-regulated in first group of comparison, italic
font = raw p-value <0.05.
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We investigated whether the dissemination of primary
tumor cells into the surrounding and growth of secondary
malignancies (metastases) affects the miRNA expression pat-
tern in blood cells. Using miRNAs with raw p-value < 0.05
we were able to differentiate between patients with and
without metastases in the adenocarcinoma and the
SCLC group with about 75% accuracy and an AUC of
0.73 and 0.82, respectively. The miRNA expression pat-
tern in blood of squamous cell lung cancer patients didno differ due to metastases. Table 3 lists the classifica-
tion results together with the corresponding miRNAs.
Effect of cigarette smoke on the miRNA expression
Cigarette smoking is the main risk factor for developing
lung cancer. However, a high proportion of adenocarcin-
oma occurs also in never smokers. We were interested if
cigarette smoking has an effect on the overall miRNA
expression pattern in patient’s blood. To address this, we
compared the miRNA expression profile of smokers and
Figure 2 Heatmap of the 50 miRNAs with highest variance and all samples. Each column represents a blood sample and each row
represents a miRNA. The miRNA expression values are visualized by the red-green color code, where green means low expression and red
means high expression. The colored bars under the dendrogram indicate the histological subtype, the smoking status, the gender, and the
metastatic state of the respective samples (red = squamous cell lung cancer (sqCLC), blue = adenocarcinoma, yellow = SCLC, pink = metastasis
(M1a or M1b), cyan = no metastasis (M0), black = no information on metastasis state, skyblue = male, darkred = female, grey = current or former
smoker, white = never-smoker).
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ment by the Benjamini-Hochberg approach, no overall
significant expression changes were observed due to
cigarette smoking among the adenocarcinoma patients.
Regarding only miRNAs with raw p-value <0.05, we iden-
tified ten miRNAs (hsa-miR-20a, hsa-miR-18b, hsa-miR-
20b, hsa-miR-17, hsa-miR-16, hsa-let-7i, hsa-miR-182,
hsa-miR-183, hsa-miR-92a, hsa-miR-151-5p) expressed in





accuracy, mean 0.7526 0.5079 0.7526
specificity, mean 0.8 0.4666 0.7792
sensitivity, mean 0.7 0.545 0.7072








Classification with linear kernel, 10-fold cross-validation, 20 repetitions using
miRNAs with raw p-value < 0.05.that were able to separate both groups with 76.8% accur-
acy and an AUC of 0.93.
Discussion
An increasing number of studies show that miRNAs from
blood can be used as biomarkers for various human dis-
eases. The spectrum of diseases analyzed includes cancer
as well as non-cancer diseases. While the majority of these
studies analyzed serum or plasma, there are also a consid-
erable number of investigations on miRNA expression in
PBMCs or whole blood. Independent of the question
whether serum, plasma, PBMCs or whole blood was ana-
lyzed, these studies provide strong evidence that blood
based miRNA signatures can be used to differentiate be-
tween controls and patients. In a comparative analysis of
blood-borne miRNA profiles in 14 diseases, we showed
recently that miRNA signatures could even differentiate
between different diseases of the same organ as for ex-
ample between lung cancer and COPD with accuracy over
90%. It was also shown that miRNA expression profiles
could not only indicate the probability of a diseases but
also the probability of the absence of a disease [23].
Tissue based miRNA expression analyses even revealed
specific miRNA expression pattern in different histological
cancer subtypes, including lung cancer. For example,
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ating transthoracic needle aspiration biopsy specimens
from NSCLC patients in adenocarcinoma and squamous
cell lung carcinoma [12]. Sets of two miRNAs accurately
discriminated between NSCLC and SCLC and between
adenocarcinoma and squamous cell lung carcinoma in
bronchial brushing specimens [13]. MiRNA analysis also
distinguished NSCLC from SCLC cell lines [15]. A small
subset of eight miRNAs classified small pre-operative bi-
opsies into squamous cell carcinoma, non-squamous
non–small cell lung cancer, carcinoid, and small cell car-
cinoma [14]. Interestingly, we found a high overlap of
deregulated miRNAs identified in the above mentioned
studies on tissue samples from different histological lung
cancer subgroups and the miRNAs detected in the blood
samples analyzed in the present study. However, there is
considerable less evidence that blood-borne miRNA signa-
tures can identify specific subcategories within a disease
as for example a specific tumor grading or histological
cancer subtypes. As a first attempt to address this ques-
tion we analyzed three histological subtypes of lung
cancer. Lung cancer was chosen since the best possible
lung cancer treatment requires accurate subclassification.
The clinically most important differentiation is between
NSCLC and SCLC as they differ not only histologically
but also in their behavior. SCLCs are very fast growing
tumors making them the most aggressive form of lung
cancer with chemotherapy or radiotherapy or a combin-
ation of both as common treatment. NSCLC treatment
depends on cancer stage; surgery is the treatment of
choice for early stage NSCLC (stage I and II) [3,4]. How-
ever, as about 70% of NSCLCs are diagnosed at advanced
stages, systemic therapy (chemo- or targeted therapy)
and/or radiation is recommended [5].
Our results show that relatively few blood-borne miR-
NAs were differentially expressed between patients with
adenocarcinoma and with squamous cell lung carcinoma,
and even less between NSCLC and SCLC. The similarity
between the miRNA signature did not allow a separation
between the different histotypes, as it was previously re-
ported for miRNAs that were derived from tumor tissues
[12-15,30-34]. Interestingly, the miRNA hsa-miR-205 that
was shown in several publications to distinguish between
tissue samples from adenocarcinoma and squamous cell
lung cancer patients was not detected in any of the
analyzed blood samples [12-15,31-34]. The results that we
obtained for the blood-borne miRNA signatures are, how-
ever, consistent with the results recently obtained for
miRNA isolated from serum that were also independent
from histology [35,36]. Serum derived miRNA signatures
showed a comparable risk of cancer death between pa-
tients with adenocarcinoma or squamous cell carcinoma.
Likewise, serum derived miRNA signatures showed a
comparable risk of cancer death between patients witheither stage I, II, or IIIa carcinomas [35]. Lin and col-
leagues [36] identified two serum miRNAs, namely hsa-
miR-126 and hsa-miR-183 that may serve as potential
serum biomarkers for metastatic non-small-cell lung
cancer. This prompted us to investigate if the miRNA ex-
pression pattern of whole blood might also be influenced
by metastases. Using a set of three to four miRNAs we
were able to differentiate between metastatic and non-
metastatic adenocarcinoma and SCLC samples, but this
was not possible for squamous cell lung cancer samples.
The two miRNAs hsa-miR-126 and hsa-miR-183 identi-
fied by Lin et al., were indeed detected in all of our ana-
lyzed samples, however, they were not included in our set
of miRNAs. A classification with these two miRNAs and
our samples was not possible. The three miRNAs that
classified between metastatic and non-metastatic adeno-
carcinoma were expressed in all analyzed blood samples,
but were all up-regulated in metastatic adenocarcinoma
(between 1.4 and 1.7 fold). These miRNAs have never
been related to cancer metastasis in literature. However,
hsa-miR-361-5p was identified to be a regulator of VEGFA
and thus associated with skin cancer [37]. The four miR-
NAs that classified between metastatic and non-metastatic
SCLC were also expressed in all analyzed blood samples.
Two miRNAs were up-regulated and two miRNAs were
down-regulated between 1.2 and 1.5 fold in metastatic
SCLC. Hsa-miR-328 that was 1.4 fold up-regulated in
metastatic SCLC has previously been shown to mediate
NSCLC migration and to be associated with NSCLC brain
metastasis [38]. In colorectal cancer tissue hsa-miR-103
might promote metastasis by targeting the known metas-
tasis suppressors death-associated protein kinase (DAPK)
and Krüppel-like factor 4 (KLF4) [39]. However, in blood
of metastatic SCLC patients, this miRNA was slightly
down-regulated (1.2 fold). The two other miRNAs hsa-
miR-15b and hsa-miR-199a-5p have not been associated
with metastasis or lung cancer.
Conclusions
Our data do not provide evidence that miRNA signatures
derived from blood can readily distinguish lung cancer
subtypes. Thus, we can conclude that blood-borne miRNA
signatures are not suitable replacements for currently used
methods for the subtyping of lung cancer. However, as ad-
dressed above miRNA signatures can be used to indicate
the presence/absence of a disease [23]. In the present
study we found a large overlap between the blood-borne
miRNAs of each histological group and the previously de-
scribed blood-borne 24-miRNA signature that separates
lung cancer patients form controls [24]. These results in-
dicate that the previously described 24-miRNA signature
for lung cancer appears not primarily dependent on histo-
logical subtypes. However, some miRNAs might be indica-
tive for the metastatic potential of adenocarcinoma and
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covered by imaging techniques like X-ray, CT, or PET that
are routinely done every few months. Alternatively, pa-
tients might meanwhile benefit from a simple blood test
that can indicate the development of a metastasis.
In summary, analyzing miRNA expression in blood
cells appears less suitable to define tumor subtypes but
to classify human cancer entities and to predict the
metastatic potential of certain histological tumor types.
Materials and methods
Patients
For the microarray analysis, we obtained 2,5 ml peripheral
blood in PAXgene Blood RNA tubes (BD, Franklin Lakes,
New Jersey USA) from 60 lung cancer patients, including
40 NSCLC patients (20 adenocarcinoma and 20 squamous
cell lung cancer) and 20 SCLC patients from Department
of Pneumology, Medical School, Saarland University. For
determining the tumor stage the 7th Edition of the UICC
TNM classification of malignant tumours was used [40].
The blood samples were drawn before therapy with the
exception of 9 patients that were formerly diagnosed with
lung cancer and already underwent therapy at that former
period. For those patients an overview is given in Table 4.
More detailed information on these patients is given in
Additional file 3: Table S2.
For the RT-qPCR validation we obtained 2,5 ml periph-
eral blood in PAXgene Blood RNA tubes (BD, Franklin
Lakes, New Jersey USA) from an independent patient co-
hort (9x adenocarcinoma, 9x squamous cell lung cancer,
5x SCLC) derived from a second institution, i.e., Depart-
ment of Thoracic Surgery, Voelklingen Heart Center.Table 4 Patient characteristics
Adenocarcinoma Squa
number of samples 20














M1a / M1b 10Informed consent was obtained from each study sub-
ject and the study was approved by the local ethics com-
mittee (Ärztekammer des Saarlandes; ID 01/08).
RNA isolation
Total RNA including miRNA was isolated using the
PAXgene Blood miRNA Kit (Qiagen) following the man-
ufacturers recommendations. Isolated RNA was stored
at -80C. RNA integrity was analyzed using Bioanalyzer
2100 (Agilent) and concentration and purity was mea-
sured using NanoDrop 2000 (Thermo Scientific).
Microarrays
Microarray analysis was performed according to the manu-
facturer’s instructions using SurePrint 8x60K Human v16
miRNA microarrays (Agilent, CatNo G4870A) that contain
40 replicates of each of the 1205 miRNAs of miRBase v16
(http://www.mirbase.org/). In brief, a total of 100 ng total
RNA was processed using the miRNA Complete Labeling
and Hyb Kit to generate fluorescently labeled miRNA.
This method involves the ligation of one Cyanine 3-pCp
molecule to the 3' end of a RNA molecule with greater
than 90% efficiency. First, the RNA is dephosphorylated
using Calf Intestinal Alkaline Phosphatase (CIP). After the
dephosphorylation step, dimethylsulfoxide (DMSO), which
is an effective RNA denaturant, is added to the samples
and the RNA is heat denaturated to minimize the effect of
structure and sequence differences among miRNAs. Using
T4 RNA ligase and a 3´,5´-cytidine bisphosphate which is
labelled by a cyanine dye at its 3´ phosphate (pCp-Cy3)
miRNA molecules with an additional 3´-cytidine and
exactly one cyanine dye on its 3´end are produced. Aftermous cell lung cancer SCLC Χ2 p-value
20 20














Leidinger et al. Molecular Cancer 2014, 13:202 Page 9 of 10
http://www.molecular-cancer.com/content/13/1/202the labeling reaction, the mixture is dried in a vacuum
centrifuge and resuspended in the hybridization mixture
containing hybridization buffer and blocking reagent.
Then the microarrays were loaded and incubated for
20 h at 55C and 20 rpm. To check if the labeling and
hybridization was successful, labeling and hybridization
spike-in controls were added in the appropriate steps.
After several washing steps microarrays were scanned
with the Agilent Microarray Scanner at 3 microns in
double path mode. Microarray scan data were further
processed using Feature Extraction software to extract
signal intensity values from the image file.Quantitative Real Time PCR (RT-qPCR)
To validate our microarray data we analyzed the expres-
sion of five miRNAs (hsa-let-7 g, hsa-miR-125b, hsa-
miR-146a, hsa-miR-20a, hsa-miR-4286) using quantita-
tive Real Time-Polymerase Chain Reaction (RT-qPCR)
using a second independent patient cohort, including 9
adenocarcinoma patients, 9 squamous cell lung cancer
patients, and 5 SCLC patients. We used the miScript
PCR System (Qiagen) for reverse transcription and RT-
qPCR. RNA was converted into cDNA using the miS-
cript II Reverse Transcription Kit and the HiSpec Buffer
according to the manufacturers´ protocol. The RT-qPCR
was performed with the miScript SYBR® Green PCR Kit
in a total volume of 20 μl per reaction containing 1 μl
diluted cDNA according to the manufacturers´ protocol.
RNU48 served as endogenous control.Statistical data evaluation
To calculate the total expression value for each miRNA
per sample we summed up the gTotalProbeSignals in
the feature extraction file, applied quantile normalization
to normalize expression values across the arrays using
the preprocessCore package of the programming lan-
guage R, and performed a log2 transformation of the
data. We carried out parametric t-test (unpaired, two-
tailed) for each miRNA separately, to detect miRNAs
that show different behavior in different groups of blood
donors. The resulting p-values were adjusted for mul-
tiple testing by Benjamini-Hochberg [41,42] adjustment.
Classification of samples using miRNA patterns was car-
ried out using Support Vector Machines (SVM, [43]) as
implemented in the R e1071 package [44] using 20 repe-
titions of standard 10-fold cross-validation and a subset
selection technique based on t-test.Additional files
Additional file 1: Figure S1. Comparison of the results obtained by
microarray and by RT-qPCR using two independent patient cohorts. The
bars correspond to the fold changes of the tested miRNAs in therespective comparison indicated above the bars (light grey = microarray
results, dark grey = RT-qPCR results).
Additional file 2: Table S1. Analysis of the overlap between the
blood-borne miRNAs that were detected in the different histological
subtypes in the present study and previously published data on
deregulated miRNAs identified in other studies on lung cancer either on
whole blood samples or on tissue specimen.
Additional file 3: Table S2. Detailed information on the 60 lung cancer
patients that were included in the microarray study.
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